Gene therapy

Biotech Jason Mast

STAT Plus: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

Biotech Jason Mast

STAT Plus: With an age cutoff for a new gene therapy, families and doctors scramble to treat kids before their 6th birthday

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Biotech Jason Mast

STAT Plus: Gene therapy is in crisis. For nine hours, the field’s leading minds looked for a solution

Biotech Jason Mast

STAT Plus: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

First Opinion Podcast Torie Bosch

Listen: One Duchenne patient’s bittersweet hope for new treatment

Biotech Adam Feuerstein

STAT Plus: BioMarin wins approval for gene therapy to treat hemophilia A

Biotech Jason Mast

STAT Plus: After promising early data, gene therapy trial for Huntington’s takes puzzling turn

Biotech Jason Mast

STAT Plus: After gene therapy deaths, Astellas brings in potentially safer treatment for muscle disorder

Biotech Megan Molteni

STAT Plus: In its first tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys

Politics John Wilkerson

STAT Plus: FDA official offers insights into whether gene therapy makers could use common manufacturing process

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

Politics Sarah Owermohle and Brittany Trang

STAT Plus: New Biden science agency ARPA-H launches first program, targeting bone regrowth

Biotech Jason Mast

STAT Plus: A new startup looks to turn the workhorse of gene therapy against cancer

Politics John Wilkerson

STAT Plus: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs

The Readout LOUD Damian Garde and Meg Tirrell

Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster

Biotech Matthew Herper

STAT Plus: Uniqure’s Huntington’s gene therapy lowers key protein in small trial

Politics Nicholas Florko

STAT Plus: FDA’s vaccines and biologics chief talks Covid-19, 2022 priorities, and getting back to gene, cell therapy review

Biotech Adam Feuerstein

STAT Plus: Patients with rare blood disorder benefit from Bluebird gene therapy while denied access in Europe

Pharmalot Ed Silverman

STAT Plus: What’s in a name? Spark Therapeutics sues Bluebird Bio over the use of the word ‘spark’

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Affinia Therapeutics raises $110 million for gene therapy treatments

Biotech Adam Feuerstein

STAT Plus: Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe

Biotech Adam Feuerstein

STAT Plus: Uniqure investigation clears hemophilia B gene therapy as cause of patient’s liver cancer

Biotech Adam Feuerstein

STAT Plus: Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients

Biotech Adam Feuerstein

STAT Plus: Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome

Biotech Kate Sheridan

STAT Plus: Startup Spotlight: Encoded eyes a gene therapy for Dravet syndrome

Biotech Adam Feuerstein

STAT Plus: New rare disease gene therapy startup recruits former Sarepta executive as CEO

Biotech Damian Garde

STAT Plus: In a shocking decision, FDA rejects BioMarin’s gene therapy for hemophilia